Acceptability of levofloxacin dispersible and non-dispersible tablet formulations in children receiving TB preventive treatment
Authors:
Open Access
- 1 February 2024
- journal article
- research article
- Published by International Union Against Tuberculosis and Lung Disease in IJTLD OPEN
- Vol. 1 (2) , 69-75
Abstract
SUMMARY: BACKGROUND: We evaluated the palatability and acceptability of a 100 mg dispersible and a non-dispersible 250 mg levofloxacin (LVX) tablet formulation in children. METHODS: Perform was a randomised, open-label, cross-over trial of the relative bioavailability of LVX dispersible vs. crushed non-dispersible tablets in children aged n = 14, 56%), vomiting/spitting out medicines ( n = 11, 44%), and children refusing medicines ( n = 10, 40%). Caregivers reported that the dispersible formulation was easier for their child to take than the non-dispersible formulation ( P = 0.0253). Mean ranks for caregiver’s formulation preferences (dispersible tablets: 1.48, SD ±0.71; non-dispersible tablets: 2.12, SD ±0.67; routinely available formulations: 2.40 SD ±0.82) differed significantly (Friedman’s F 11.120; P < 0.0038); post-hoc testing showed dispersible tablets were preferred over non-dispersible ( P = 0.018) and routinely available LVX formulations ( P < 0.001). CONCLUSIONS: The dispersible LVX 100 mg tablet formulation was preferred and should be prioritised for integration into routine care.Keywords
This publication has 35 references indexed in Scilit:
- Tuberculosis Preventive Therapy for Individuals Exposed to Drug-resistant Tuberculosis: Feasibility and Safety of a Community-based Delivery of Fluoroquinolone-containing Preventive RegimenClinical Infectious Diseases, 2019
- Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant TuberculosisThe Pediatric Infectious Disease Journal, 2019
- Global burden of drug-resistant tuberculosis in children: a mathematical modelling studyThe Lancet Infectious Diseases, 2016
- Fluoroquinolones for the treatment of tuberculosis in childrenTuberculosis, 2015
- Patient-centred, administration friendly medicines for children – An evaluation of children’s preferences and how they impact medication adherenceInternational Journal of Pharmaceutics, 2014
- Regulatory perspectives on acceptability testing of dosage forms in childrenInternational Journal of Pharmaceutics, 2014
- Pharmacokinetics of Ofloxacin and Levofloxacin for Prevention and Treatment of Multidrug-Resistant Tuberculosis in ChildrenAntimicrobial Agents and Chemotherapy, 2014
- The Bad Taste of Medicines: Overview of Basic Research on Bitter TasteClinical Therapeutics, 2013
- Levofloxacin, a Second‐Generation FluoroquinolonePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1998
- In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 1995